Table 1.
Characteristics of studies included for systematic review and meta-analysis
| Author & year | Country | Study Design & population | Study period | No of cases (% of Males) | No ofcontrols (% of Males) | Method of AF exposure assessment | Unadjusted OR (95%CI) | Adjusted OR (95%CI) | Adjusted variables | Result of critical appraisal |
|---|---|---|---|---|---|---|---|---|---|---|
| Wang, 2018 [22] | China | Hospital based case-control | 2008–2012 | 384 (75.3) | 851 (75.7) | AF-albumin adduct | 7.74 (5.51–10.87) | a | a | Low risk |
| Chu, 2017 [12] | Taiwan | Community-based nested case-control | 1991–2004 | 232 (a) | 577 (a) | AF-albumin adduct | 2.29 (1.44–3.64) | 2.45 (1.51–3.98) | Age, gender, cigarette smoking, alcohol drinking, ALT | Low risk |
| Anitha, 2014 [21] | India | Hospital based case-control | 2009–2010 | 130 (a) | 108 (a) | AF-albumin adduct | 3.59 (1.56–8.23) | a | a | Low risk |
| 249ser TP53 mutation | 3.46 (0.72–16.7) | |||||||||
| Kuniholm, 2008 [20] | Gambia | Hospital based case-control | 1997–2001 | 97 (62.9) | 397 (71) | 249ser TP53 mutation | 3.9 (1.8–8.4) | 3.8 (1.5–9.6) | Age, gender, recruitment site & date, socioeconomic status, alcohol, tobacco, HBV, HCV | Low risk |
| Ground nut intake | 2.6 (1.2–5.8) | 2.8 (1.1–7.7) | ||||||||
| Kirk, 2005 [19] | Gambia | Hospital based case-control | 1997–2001 | 98 (65.3) | 348 (69.8) | 249ser TP53 mutation | 5.06 (2.28–11.22) | 4.83 (1.71–13.7) | Age, gender, recruitment date & site, ethnicity, alcohol, socioeconomic status, HBV & HCV status | Low risk |
| Ground nut intake | 0.8546 (0.53–1.37) | 1.79 (1.04–3.08) |
Abbreviations: AF Aflatoxin, ALT Alanine transaminase, HBV Hepatitis B virus, HCV Hepatitis C virus
aNot reported